A Phase 3, Modified-double Blind, Multi-center Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers (2 to 23 Months of Age) in China

The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China.
Study details include:
* Study duration (including 6-month safety follow-up after the last dose): - Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months) - Cohort II (Groups 3 and 4): up to 18 months - Cohort III (Groups 5 and 6): up to 21 months - Cohort III (Group 7): approximately 16 months
* Vaccination Visits Period:
* Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121). Telephone calls (TCs) are planned on the 4th, the 9th, and the 21st day after each vaccination, and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit for safety follow-up. For participants receiving the second vaccination with a 3-month interval: an on-site visit is planned 30 days post the 1st dose of vaccination (V02, D31) for participant diary collection.
* Cohort II (Groups 3 and 4): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). A 1-dose booster is planned for Group 3 only at 18 MoA (within the 18th month from the participant's birth date). Up to 4 blood samples will be collected. In the primary vaccination period, blood samples are collected before the first primary vaccination (D01) and 30 days post the 2nd dose of primary vaccination (D61 or D121). A blood sample will be collected from all participants at 18 MoA. A post-booster blood sample will be collected from participants in Group 3, 30 days post their booster vaccination. Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods, respectively, for safety follow-up. For participants receiving the second vaccination with a 3-month interval: an on-site visit is planned 30 days post the 1st dose of vaccination (V02, D31) for participant diary collection. - Cohort III - Groups 5 and 6: a 3-dose primary vaccination at V01 (D01), V02 (D31) and V03 (D61), a 1-dose booster at 12 MoA (within the 12th months from the participant's birth date) on V05 or at 18 MoA (within the 18th months from the participant's birth date) on V06.
In total 4 blood samples are to be collected. In the primary vaccination period, blood samples are to be collected before the first primary vaccination (D01) and 30 days post the 3rd dose of primary vaccination (D91); in the booster vaccination period, blood samples are to be collected before booster vaccination at V05 (for participants receiving the booster at 12 MoA) or V06 (for participants receiving the booster at 18 MoA), and 30 days post booster vaccination (V05 + 30 days or V06 + 30 days). Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods respectively for safety follow-up.
- Cohort III - Group 7: a 3-dose primary vaccination at V01 (D01), V02 (D61) and V03 (D121), a 1-dose booster at V05 at 12 MoA (within the 12th months from the participant's birth date).
In total 4 blood samples are to be collected. In the primary vaccination period, blood samples are to be collected before the first primary vaccination (D01) and 30 days post the 3rd dose of primary vaccination (D151); in the booster vaccination period, blood samples are to be collected before booster vaccination at V05 and 30 days post booster vaccination (V06). Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods (ie, V04 and V06), respectively, for safety follow-up. A safety visit is planned on the 9th day after the first vaccination for the ESDR participants (the first 30 participants in this group).

Start Date20 Aug 2026

Sponsor / Collaborator

Sanofi

NCT07621653

/ Not yet recruitingNot Applicable

Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea

This surveillance is to investigate the safety profile of MenQuadfi®, when administered to participants aged 6 weeks to 55 years under the real-world clinical practice settings as per approved indications, including the Adverse Drug Reactions (ADRs)*.
*It includes ADRs that were not fully recognized in clinical practice, or unexpected ADRs which refer to those not listed in the approved drug labeling.

Start Date27 May 2026

Sponsor / Collaborator

Sanofi

NCT07135986

/ Active, not recruitingPhase 3

A Phase 3, Modified Double-blind, Multi-center Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents (2 to 17 Years of Age) in China

This is a Phase 3, modified double-blind, randomized, parallel-group, active-controlled, multicenter study with 2 arms and 4 groups to evaluate the immunogenicity and safety of MenACYW conjugate vaccine in children and adolescents versus control meningococcal vaccines licensed in China.
Study details include:
* The study duration will be approximately 180 days.
* The vaccination visit will be Visit 1.
* The visit frequency will be 2 on-site visits with a 30-day interval. A safety visit/telephone call is planned on the ninth day after the vaccination for all groups; a safety follow-up telephone call is planned for all groups 180 days post the last vaccination.

Start Date26 Sep 2025

Sponsor / Collaborator

Sanofi

100 Clinical Results associated with Meningococcal vaccine groups A C Y W-135 conjugate (second generation)(Sanofi)

100 Translational Medicine associated with Meningococcal vaccine groups A C Y W-135 conjugate (second generation)(Sanofi)

100 Patents (Medical) associated with Meningococcal vaccine groups A C Y W-135 conjugate (second generation)(Sanofi)

113

Literatures (Medical) associated with Meningococcal vaccine groups A C Y W-135 conjugate (second generation)(Sanofi)

31 Dec 2025·Human Vaccines & Immunotherapeutics

A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT)

Review

Author: Tezer, Hasan ; Somer, Ayper ; Ciftci, Ergin ; Dinleyici, Ener Cagri ; Yilmaz, Dilek

Neisseria meningitidis (Nm) remains a major global health concern, causing invasive meningococcal disease (IMD) with significant morbidity and mortality. Despite vaccination efforts, Nm serogroup prevalence and antibiotic resistance continue to evolve, necessitating ongoing surveillance and novel immunization strategies. This review aims to assess the role of MenACWY-TT, a quadrivalent meningococcal conjugate vaccine, in IMD prevention by evaluating its immunogenicity, safety, and real-world effectiveness. The objectives include analyzing its advantages over existing vaccines, identifying gaps in long-term immunity data, and assessing its potential integration into National Immunization Programs (NIPs). MenACWY-TT has demonstrated strong immunogenicity, a favorable safety profile, and ease of administration with its liquid, non-adjuvanted formulation. Real-world studies show high vaccine effectiveness and herd protection benefits. However, further research is needed to evaluate long-term immunity and efficacy in high-risk populations.

31 Dec 2025·Human Vaccines & Immunotherapeutics

Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study

Article

Author: Kharit, Susanna ; Singh Dhingra, Mandeep ; Syrkina, Olga ; Rehm, Christine ; Lyabis, Olga ; Zambrano, Betzana ; Villagomez-Martinez, Sandra ; Galustyan, Anna ; B’Chir, Siham

MenACYW-TT (MenQuadfi®), a quadrivalent meningococcal conjugate vaccine, is approved for use in individuals aged ≥12 months or ≥6 weeks depending on the country. This study reported the immunogenicity and safety of MenACYW-TT in individuals aged <12 months. This phase III, open-label, randomized, active-controlled study described the immunogenicity and safety of a 3-dose (2 + 1) immunization schedule of MenACYW-TT in Mexico and the Russian Federation or a 4-dose (3 + 1) immunization schedule of MCV4-CRM in Mexico, when co-administered with routine pediatric vaccines to healthy infants and toddlers aged 2 to 12 months (NCT03630705). The immunogenicity of meningococcal serogroups was assessed by serum bactericidal antibody assays using human complement. The safety data were collected for up to 30 d following vaccination. MenACYW-TT demonstrated high seroprotection rates in Mexico and in the Russian Federation after the last vaccination (booster) at 12 months of age. The proportion of participants achieving seroresponse to all 4 meningococcal serogroups after receiving 2 doses of MenACYW-TT in the infant series was comparable to the proportion of those receiving 3 doses of MCV4-CRM in Mexico. There was no clinically relevant effect on the immunogenicity and safety profile of the routine pediatric vaccines when administered concomitantly with MenACYW-TT at the same visit. No safety concern was observed during this study. MenACYW-TT demonstrated a safety profile generally comparable with that of MCV4-CRM when administered concomitantly with routine pediatric vaccines. The MenACYW-TT conjugate vaccine in a 2 + 1 schedule demonstrated an acceptable immunogenicity and safety profile.

31 Dec 2025·Human Vaccines & Immunotherapeutics

A Phase 3 study to assess the safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in healthy infants in the USA and Puerto Rico

Article

Author: Campbell, James D. ; Zambrano, Betzana ; Rehm, Christine ; Gan, Lucia ; Liabis, Olga ; Dhingra, Mandeep Singh ; Masson, Julie ; Syrkina, Olga ; Gupta, Sandeep ; B’Chir, Siham ; Chaix, Julie

A quadrivalent meningococcal tetanus toxoid-conjugate vaccine, MenACYW-TT, has been developed to provide protection against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. This Phase 3 study (NCT03537508; April 25, 2018, to September 22, 2023) evaluated the immunogenicity and safety of MenACYW-TT, compared with a licensed quadrivalent meningococcal oligosaccharide diphtheria CRM₁₉₇-conjugate vaccine (MenACWY-CRM), in healthy infants ≥6 weeks of age when administered concomitantly with routine pediatric vaccines in a four-dose series (3 + 1 schedule). Functional antibodies against each meningococcal serogroup were measured by serum bactericidal antibody assay using human complement (hSBA). Non-inferiority was demonstrated for the first co-primary endpoint of seroresponse rates 30 days after the fourth dose at 12-15 months of age, with serogroup-specific seroresponse rates of 79.4%-97.6% and 77.6%-96.4% for MenACYW-TT and MenACWY-CRM, respectively. Non-inferiority was also demonstrated for the second co-primary endpoint based on proportions of participants with hSBA antibody titers ≥1:8 against each serogroup 30 days after the third dose at 6 months of age, with rates of 77.9-99.0% for MenACYW-TT and 67.7-92.9% for MenACWY-CRM. After four doses, hSBA geometric mean titers were comparable for serogroup A and higher for serogroups C, W, and Y with MenACYW-TT versus MenACWY-CRM. Immune responses to all routine pediatric vaccines administered concomitantly with MenACYW-TT were non-inferior to those following concomitant administration with MenACWY-CRM. MenACYW-TT and MenACWY-CRM were overall well tolerated, and the safety profiles of these vaccines were comparable. This study supports the use of MenACYW-TT in infants aged 6 weeks (42 days) or older.Study registration: ClinicalTrials.gov: NCT03537508.

News (Medical) associated with Meningococcal vaccine groups A C Y W-135 conjugate (second generation)(Sanofi)

12 Mar 2026

·www.skbioscience.com

SK bioscience Hosts Nationwide Forum for Healthcare Professionals to Raise Awareness of Meningococcal Disease

Forums for clinicians to be held in Busan, followed by Gwangju, Daegu, and Jeonju to share prevention strategies and latest medical insights Emphasizing the importance of preventing invasive meningococcal disease; introducing the quadrivalent conjugate vaccine MenQuadfi® “We will continue academic exchange with frontline healthcare professionals to improve awareness of meningococcal disease” SK bioscience will host a nationwide forum for healthcare professionals to raise awareness of meningococcal disease and the importance of vaccination. The company announced on the 12th that it will hold a series of academic forums for clinicians in hospitals and local clinics across major regions?including Busan, Gwangju, Daegu, and Jeonju?from March 5 through April 19, starting in Busan. The forums aim to share strategies for preventing meningococcal disease and provide the latest clinical insights. The forum was organized to discuss the global and domestic epidemiology and transmission patterns of invasive meningococcal disease (IMD) as well as the importance of vaccination, while also exploring prevention strategies that can be applied in real-world clinical settings. At the first forum in Busan, Professor Soo Eun Park of Pusan National University Yangsan Hospital will chair the session, delivering lectures and leading discussions to share the latest academic findings with participating healthcare professionals. Meningococcal infection is a severe bacterial disease that can cause acute meningitis or sepsis and is characterized by its rapid progression, often worsening within hours after onset. The disease has a high fatality rate, and survivors may experience serious long-term complications such as hearing loss, neurological disorders, or limb amputation. As a result, the importance of vaccination as a preventive measure is strongly emphasized. The risk of infection is known to increase in communal living environments, such as dormitories or military service. During the forum, clinical data and real-world vaccination experience with the quadrivalent meningococcal conjugate vaccine MenQuadfi®, which protects against meningococcal serogroups A, C, W, and Y, will also be introduced. Developed by global biopharmaceutical company Sanofi, MenQuadfi is supplied in Korea for infants and children by SK bioscience. As a conjugate vaccine covering major meningococcal serogroups, it can be administered starting from six weeks of age, expanding vaccination options for infants and young children. Professor Soo Eun Park, who will chair the first forum session, said, “Awareness of meningococcal disease in Korea remains relatively low, while vaccination recommendations are expanding overseas, particularly among adolescents and young adults. I hope this forum will serve as an opportunity to share the latest medical insights with regional healthcare professionals and promote a prevention-centered approach to infectious disease response.” Dr. Sumin Kang, Director of Saessak Pediatrics Clinic in Busan who attended the event, said, “Although meningococcal disease is not highly prevalent, it can be fatal once it occurs, making proactive prevention through vaccination extremely important. In particular, healthcare professionals need to provide active guidance to adolescents and those living in communal environments.” Sooan Yoo, Head of Domestic Marketing at SK bioscience, said, “Because meningococcal disease is difficult to predict and progresses rapidly, vaccination remains the most effective preventive measure. Through continuous academic exchange with healthcare professionals nationwide, we will work to improve awareness of meningococcal disease and support the active use of preventive strategies?including MenQuadfi?in clinical practice.” SK bioscience plans to further expand academic activities and educational programs for healthcare professionals to raise awareness of infectious disease prevention and contribute to improving the vaccination environment in Korea.

Vaccine

09 Jan 2026

·www.skbioscience.com

SK bioscience and Sanofi Launch MenQuadfi Meningococcal Vaccine in Korea

Introduction in Korea of MenQuadfi, a quadrivalent meningococcal conjugate vaccine eligible for use from 6 weeks of age Expansion of infant and pediatric immunization portfolios in line with global vaccination practices Establishment of a proactive infectious disease prevention strategy and growth objectives based on domestic and global partnerships SK bioscience announced the new domestic launch of MenQuadfi Injection (MenQuadfi, MenACWY-TT), a quadrivalent meningococcal conjugate vaccine, in partnership with the Korean affiliate of global biopharmaceutical company Sanofi. Developed by Sanofi, MenQuadfi is approved for use in individuals from 6 weeks of age through 55 years and is indicated for the prevention of Invasive Meningococcal Disease (IMD) caused by the major meningococcal serogroups A, C, W, and Y. Notably, among A, C, W, Y meningococcal vaccines approved in Korea, MenQuadfi is the only product that both includes serogroup A and is approved for use in infants aged 6 weeks to under 24 months. SK bioscience will be responsible for the domestic distribution and supply of the vaccine for infant and pediatric populations. MenQuadfi is distinguished by its fully liquid formulation, allowing for direct administration without the need for reconstitution. This simplifies vaccine preparation, enhances clinical workflow efficiency, and helps reduce the risk of preparation-related errors in healthcare settings. The vaccine is administered as a 0.5 mL intramuscular injection, with dosing schedules as follows: -Infants aged 6 weeks to under 6 months: a total of four doses-Infants aged 6 months to under 24 months: two doses- Individuals aged 2 to 55 years: one dose Meningococcal disease is transmitted through respiratory secretions, such as nasal discharge or saliva, and can be spread even by asymptomatic carriers, underscoring the importance of prevention. The bacterium may colonize the nasopharynx without symptoms and, under certain conditions, invade the bloodstream or central nervous system, leading to meningitis or septicemia. The risk of transmission is particularly elevated in close-contact settings, including households and communal living environments. Reflecting these characteristics, major developed countries?including the United States, United Kingdom, Australia, and Canada?have incorporated meningococcal vaccination for infants, children, and adolescents into national immunization programs or administer it as part of officially recommended routine vaccination schedules. This approach represents a proactive prevention strategy, accounting for the disease’s unpredictable transmission patterns, high case-fatality rates, and the burden of long-term sequelae. In Korea, the Korea Disease Control and Prevention Agency (KDCA) recommends meningococcal vaccination for individuals at increased risk of infection, including immunocompromised patients, laboratory personnel, new military recruits, university dormitory residents, travelers to or residents of endemic regions, and close contacts during outbreaks. Jaeyong Ahn, CEO of SK bioscience said “Through the introduction of MenQuadfi, we have expanded preventive options against invasive meningococcal disease for infants and children in Korea. Going forward, we will continue to strengthen the domestic infectious disease prevention environment through global partnerships and ensure a stable supply of vaccines that contribute to public health advancement.” SK bioscience has been supplying a range of infant and pediatric vaccines in Korea in collaboration with Sanofi, including the hexavalent combination vaccine Hexaxim. Since last year, the company has also launched Beyfortus, a monoclonal antibody injection for RSV prevention, expanding its use primarily among infants. Leveraging a portfolio that spans both vaccines and preventive antibodies, SK bioscience plans to respond with an increasingly proactive prevention strategy to major infectious diseases threatening the health of infants and children in Korea. SK bioscience announced the new domestic launch of MenQuadfi Injection (MenQuadfi, MenACWY-TT), a quadrivalent meningococcal conjugate vaccine, in partnership with the Korean affiliate of global biopharmaceutical company Sanofi. Developed by Sanofi, MenQuadfi is approved for use in individuals from 6 weeks of age through 55 years and is indicated for the prevention of Invasive Meningococcal Disease (IMD) caused by the major meningococcal serogroups A, C, W, and Y. Notably, among A, C, W, Y meningococcal vaccines approved in Korea, MenQuadfi is the only product that both includes serogroup A and is approved for use in infants aged 6 weeks to under 24 months. SK bioscience will be responsible for the domestic distribution and supply of the vaccine for infant and pediatric populations. MenQuadfi is distinguished by its fully liquid formulation, allowing for direct administration without the need for reconstitution. This simplifies vaccine preparation, enhances clinical workflow efficiency, and helps reduce the risk of preparation-related errors in healthcare settings. The vaccine is administered as a 0.5 mL intramuscular injection, with dosing schedules as follows: -Infants aged 6 weeks to under 6 months: a total of four doses -Infants aged 6 months to under 24 months: two doses - Individuals aged 2 to 55 years: one dose Meningococcal disease is transmitted through respiratory secretions, such as nasal discharge or saliva, and can be spread even by asymptomatic carriers, underscoring the importance of prevention. The bacterium may colonize the nasopharynx without symptoms and, under certain conditions, invade the bloodstream or central nervous system, leading to meningitis or septicemia. The risk of transmission is particularly elevated in close-contact settings, including households and communal living environments. Reflecting these characteristics, major developed countries?including the United States, United Kingdom, Australia, and Canada?have incorporated meningococcal vaccination for infants, children, and adolescents into national immunization programs or administer it as part of officially recommended routine vaccination schedules. This approach represents a proactive prevention strategy, accounting for the disease’s unpredictable transmission patterns, high case-fatality rates, and the burden of long-term sequelae. In Korea, the Korea Disease Control and Prevention Agency (KDCA) recommends meningococcal vaccination for individuals at increased risk of infection, including immunocompromised patients, laboratory personnel, new military recruits, university dormitory residents, travelers to or residents of endemic regions, and close contacts during outbreaks. Jaeyong Ahn, CEO of SK bioscience said “Through the introduction of MenQuadfi, we have expanded preventive options against invasive meningococcal disease for infants and children in Korea. Going forward, we will continue to strengthen the domestic infectious disease prevention environment through global partnerships and ensure a stable supply of vaccines that contribute to public health advancement.” SK bioscience has been supplying a range of infant and pediatric vaccines in Korea in collaboration with Sanofi, including the hexavalent combination vaccine Hexaxim. Since last year, the company has also launched Beyfortus, a monoclonal antibody injection for RSV prevention, expanding its use primarily among infants. Leveraging a portfolio that spans both vaccines and preventive antibodies, SK bioscience plans to respond with an increasingly proactive prevention strategy to major infectious diseases threatening the health of infants and children in Korea.

Drug ApprovalVaccine

20 Aug 2025

·www.drugs.com

Tdap, MenACWY Coverage Increased in Teens From 2023 to 2024

TUESDAY, Aug. 19, 2025 -- From 2023 to 2024, coverage with one or more doses of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) and the quadrivalent meningococcal conjugate vaccine (MenACWY) increased, while human papillomavirus (HPV) vaccination coverage remained stable, according to research published in the Aug. 14 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report . Cassandra Pingali, M.P.H., from the CDC in Atlanta, and colleagues analyzed data from the 2024 National Immunization Survey-Teen to examine national, state, and selected local area vaccination coverage in 2024. Data were included for 16,325 adolescents aged 13 to 17 years. The researchers found that coverage with one or more Tdap dose increased from 89.0 to 91.3 percent from 2023 to 2024; coverage with one or more MenACWY doses increased from 88.4 to 90.1 percent. For the third consecutive year, HPV vaccination coverage remained stable, with 78.2 and 62.9 percent of adolescents having received one or more doses and being up to date with the HPV vaccination series, respectively. Coverage with one or more Tdap doses and one or more MenACWY doses was ≥90 percent in 39 and 30 states, respectively, while coverage with one or more dose of the HPV vaccine was ≥80 percent in 26 states and the District of Columbia. Lower HPV vaccination coverage in nonmetropolitan statistical areas (MSAs) persisted compared with that seen in MSA principal cities. "Health departments can work with health care providers and communities to improve local vaccine access and increase adolescent vaccination coverage," the authors write. Abstract/Full Text

Vaccine

100 Deals associated with Meningococcal vaccine groups A C Y W-135 conjugate (second generation)(Sanofi)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07AH08	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Meningococcal Infections	Canada	Sanofi Pasteur, Inc.	29 Oct 2020
Invasive meningococcal disease	United States	Sanofi Pasteur, Inc.	23 Apr 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Meningitis, Meningococcal	NDA/BLA	European Union	Sanofi Winthrop Industrie SA	-
Meningitis	Phase 2	United States	Sanofi Pasteur SA	16 Dec 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05929651 (CTgov)	Phase 4	Meningococcal Infections	71	MenACYW conjugate vaccine	abjndeooeu = mxamcgwpsc hpfrzmybum (lsaiuabwwr, pbdzjrzcip - qdgxrbdeak) View more	-	22 Sep 2025
NCT06228586 (CTgov)	Phase 3	Meningococcal Infections	447	MenACYW Conjugate Vaccine (MenACYW Conjugate Vaccine: 12-23 Months of Age)	yvlkqstfqj(ihjdnlozks) = nxytyunind utujawxgzz (qinagywpew, virjxeosep - wvnkellzsl) View more	-	17 Sep 2025
				MenACYW Conjugate Vaccine (MenACYW Conjugate Vaccine: 24 Months of Age and Above)	yvlkqstfqj(ihjdnlozks) = fpvtqoirke utujawxgzz (qinagywpew, mmmimeyfnb - kkqnwowwlv) View more
NCT03869866 (MEQ00063, CTgov)	Phase 3	Meningococcal Infections	290	Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine	kqsxbzlsln = awyfebezqe rqltssktjf (powvcmnlwf, imgvdblzgi - adelgeuwum) View more	-	17 Mar 2025
NCT04143061 (MET55, CTgov)	Phase 3	Meningococcal Infections	1,328	MenACYW Conjugate Vaccine (Group 5 + Group 7: MenACYW Conjugate Vaccine)	vauibkwxvj = yveyfysdxv fabydmhkks (abllslevvw, rrylpmnuiv - xhevwzqmjh) View more	-	03 Feb 2025
				Menactra (Group 6 + Group 8: Menactra®)	vauibkwxvj = zgesqfeqtd fabydmhkks (abllslevvw, lbajsiqlrb - oandpmzfmd) View more
NCT03547271 (CTgov)	Phase 3	Meningococcal Infections	1,660	Pneumococcal vaccine (10-valent)+MenACYW conjugate vaccine+DTaP-IPV-HB-Hib vaccine+MMR vaccine (Group 1: MenACYW)	mvfyoijfrt(coofjvjiqk) = mwhtsmilov yrxzkibemm (qpwdpdkrrc, hyxlbqdofk - bngwsqplos) View more	-	22 Jan 2025
				Pneumococcal vaccine (10-valent)+DTaP-IPV-HB-Hib vaccine+Meningococcal group A, C, W-135, and Y conjugate vaccine+MMR vaccine (Group 2: Nimenrix)	mvfyoijfrt(coofjvjiqk) = iwmqoppzka yrxzkibemm (qpwdpdkrrc, vgvgvsxpxz - bebhvkmeof) View more
NCT03537508 (CTgov)	Phase 3	Meningococcal Infections	2,627	MenACYW Conjugate Vaccine (Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination))	wdqjwkjfeu = cdlonzvbds xehfklweti (xfxkvdroqx, ggqyegtfcc - qnqzufwyqp) View more	-	15 Oct 2024
				MENVEO (Group 2a: MENVEO (Post 12-month Vaccination))	wdqjwkjfeu = phxwxntiyk xehfklweti (xfxkvdroqx, qxzsckozlu - pvwjlwxxak) View more
NCT03691610 (CTgov)	Phase 3	Meningococcal Infections	950	MenACYW conjugate vaccine (Infants: Group 1)	uumdqhjiwc = gujxphwpqp gthdotybjl (hewksihygv, efoejqsmjz - hpjehvehqn) View more	-	25 Jun 2024
				MENVEO (Infants: Group 2)	uumdqhjiwc = clgbgkdvjq gthdotybjl (hewksihygv, cxerpfxwbx - hnnnxzrsdz) View more
NCT03632720 (CTgov)	Phase 3	Meningococcal Infections	788	Meningococcal group B vaccine+Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine+Human rotavirus RIX4414 strain vaccine+Pneumococcal 13-valent polysaccharide conjugate vaccine (Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months))	poczgqfikr = pabxltphox dgwlwtilhh (xbmjezrkee, tweqnzzafn - vgioniljgn) View more	-	07 Nov 2023
				Meningococcal group B vaccine+Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine+Human rotavirus RIX4414 strain vaccine+Pneumococcal 13-valent polysaccharide conjugate vaccine (Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months))	poczgqfikr = cwcloscscv dgwlwtilhh (xbmjezrkee, jcmzfuwbif - vctexhyfyx) View more
NCT03630705 (MET33, CTgov)	Phase 3	Meningococcal Infections	525	Meningococcal Polysaccharide (Serogroups A, C, Y, and W)+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine+Pneumococcal 13-valent Conjugate Vaccine+Rotavirus Vaccine, Live, Pentavalent (Group 1: MenACYW Conjugate Vaccine (Mexico))	wirxildhlv = pzdlkmmhue gqkgfdmkfb (gmkijsprtv, pmebbqkrfj - orinidfony) View more	-	19 Oct 2023
				Meningococcal Polysaccharide (Serogroups A, C, Y, and W)+Measles, Mumps, and Rubella Virus Vaccine Live+Hepatitis B Vaccine+Haemophilus influenza type b Conjugate Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Group 3: MenACYW Conjugate Vaccine (Russian Federation))	webmcpvnkp = rvaqxguorq vlngfucsjq (dqnkpfwnjh, zxbspbexmg - ghzsevidxa) View more
NCT03673462 (MET41, CTgov)	Phase 3	Meningococcal Infections	2,797	Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)+Hepatitis B Vaccine+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine+Varicella Virus Vaccine+Rotavirus Vaccine+Pneumococcal 13-valent Conjugate Vaccine+Measles, Mumps, and Rubella Virus Vaccine (Group 1: MenACYW Conjugate Vaccine)	xxhnbpqrto = lufohncveq mwquoxgmsx (arrwztnwgc, esrzikiznt - qikxjelpgf) View more	-	05 Oct 2023
				Hepatitis B Vaccine+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine+Varicella Virus Vaccine+Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)+Rotavirus Vaccine+Pneumococcal 13-valent Conjugate Vaccine+Measles, Mumps, and Rubella Virus Vaccine (Group 2: MENVEO®)	xxhnbpqrto = tnnrtadpwe mwquoxgmsx (arrwztnwgc, gttqmcfniz - fxxsvikxbz) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis